Last reviewed 2026-04-20 · How we verify

Anti-androgen

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Fatigue
• Anaemia
• Nausea
• Bone pain
• Diarrhoea
• Constipation
• Hypertension
• Alopecia
• Arthralgia
• Oedema peripheral
• Vomiting
• Neutrophil count decreased

Key clinical trials

• Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment (PHASE3)
• Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer (PHASE2)
• PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer (PHASE2, PHASE3)
• PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer (PHASE2, PHASE3)
• Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study (PHASE3)
• Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer (NA)
• Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (PHASE2)
• Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Anti-androgen CI brief — competitive landscape report
• Anti-androgen updates RSS · CI watch RSS
• Radiation Therapy Oncology Group portfolio CI